

Estela Giménez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030930/publications.pdf>

Version: 2024-02-01

73
papers

1,045
citations

430874

18
h-index

552781

26
g-index

73
all docs

73
docs citations

73
times ranked

1470
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1139-1149.	4.7	57
2	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019, 19, 2479-2494.	4.7	45
3	Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Clinical Virology</i> , 2017, 94, 22-28.	3.1	44
4	Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 207-209.	1.8	43
5	Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. <i>Journal of Medical Virology</i> , 2014, 86, 838-844.	5.0	39
6	Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw107.	0.9	36
7	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1894-1903.	5.8	36
8	An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. <i>Future Virology</i> , 2015, 10, 113-134.	1.8	33
9	Early Kinetics of Plasma Cytomegalovirus DNA Load in Allogeneic Stem Cell Transplant Recipients in the Era of Highly Sensitive Real-Time PCR Assays: Does It Have Any Clinical Value?. <i>Journal of Clinical Microbiology</i> , 2014, 52, 654-656.	3.9	31
10	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 563-570.	2.0	31
11	Role of cytomegalovirus (CMV)-specific polyfunctional CD8 ⁺ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. <i>Journal of General Virology</i> , 2015, 96, 2822-2831.	2.9	29
12	Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. <i>Transplant Infectious Disease</i> , 2017, 19, e12773.	1.7	26
13	Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 ⁺ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5602-5605.	3.2	24
14	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018, 20, e12926.	1.7	24
15	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2885-2894.	4.7	22
16	Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 40-43.	1.8	21
17	An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting. <i>Journal of Medical Virology</i> , 2014, 86, 568-575.	5.0	19
18	Evaluation of the Architect Epstein-Barr Virus (EBV) Viral Capsid Antigen (VCA) IgG, VCA IgM, and EBV Nuclear Antigen 1 IgG Chemiluminescent Immunoassays for Detection of EBV Antibodies and Categorization of EBV Infection Status Using Immunofluorescence Assays as the Reference Method. <i>Vaccine Journal</i> , 2014, 21, 684-688.	3.1	19

#	ARTICLE	IF	CITATIONS
19	Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCPê1, ILê10, and TLR9 genes. <i>Journal of Medical Virology</i> , 2015, 87, 248-255.	5.0	19
20	Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. <i>Medical Microbiology and Immunology</i> , 2019, 208, 253-258.	4.8	19
21	Impact of cytomegalovirus <scp>DNA</scp>emia on overall and nonêrelapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12717.	1.7	18
22	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13158.	1.7	17
23	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	3.3	17
24	SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19.. <i>Transplantation</i> , 2021, Publish Ahead of Print, 1372-1380.	1.0	17
25	T cellêmediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 2785-2794.	4.7	17
26	Early kinetics of Torque Teno virus DNA load and BK polyomavirus viremia after kidney transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13240.	1.7	16
27	Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2741-2744.	3.9	15
28	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018, 90, 1438-1443.	5.0	15
29	Short-term incubation of positive blood cultures in brain-heart infusion broth accelerates identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry. <i>Journal of Medical Microbiology</i> , 2017, 66, 1752-1758.	1.8	15
30	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 431-440.	2.4	13
31	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with postêtransplantation cyclophosphamide. <i>Transplant Infectious Disease</i> , 2020, 22, e13206.	1.7	13
32	Comparison of the artus EpsteinêBarr virus (EBV) PCR kit and the Abbott RealTime EBV assay for measuring plasma EBV DNA loads in allogeneic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 36-38.	1.8	12
33	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. <i>Clinical Infectious Diseases</i> , 2018, 67, 805-807.	5.8	12
34	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2019, 54, 90-98.	2.4	12
35	Suitability of two rapid lateral flow immunochromatographic assays for predicting SARSêCoVê2 neutralizing activity of sera. <i>Journal of Medical Virology</i> , 2021, 93, 2301-2306.	5.0	12
36	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11

#	ARTICLE	IF	CITATIONS
37	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 972-977.	2.0	11
38	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. <i>American Journal of Transplantation</i> , 2021, 21, 258-271.	4.7	11
39	IL28B genetic variation and cytomegalovirus-specific T cell immunity in allogeneic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2017, 89, 685-695.	5.0	10
40	The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of General Virology</i> , 2017, 98, 2530-2542.	2.9	10
41	Would Kinetic Analyses of Plasma Cytomegalovirus DNA Load Help to Reach Consensus Criteria for Triggering the Initiation of Preemptive Antiviral Therapy in Transplant Recipients?: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 1533-1535.	5.8	9
42	Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?. <i>Journal of Clinical Virology</i> , 2017, 97, 26-32.	3.1	9
43	Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	9
44	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1347-1356.	2.4	9
45	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020, 209, 15-21.	4.8	8
46	Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2021, 93, 5167-5172.	5.0	8
47	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) proteomic profiling of cerebrospinal fluid in the diagnosis of enteroviral meningitis: a proof-of-principle study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2331-2339.	2.9	7
48	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 23, e13507.	1.7	7
49	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13301.	1.7	7
50	Performance of a MALDI-TOF mass spectrometry-based method for rapid detection of third-generation oxymino-cephalosporin-resistant <i>Escherichia coli</i> and <i>Klebsiella</i> spp. from blood cultures. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1925-1932.	2.9	7
51	Plasma metabolomics profiling for the prediction of cytomegalovirus DNAemia and analysis of virus-host interaction in allogeneic stem cell transplant recipients. <i>Journal of General Virology</i> , 2015, 96, 3373-3381.	2.9	6
52	Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia. <i>Journal of Medical Virology</i> , 2015, 87, 1601-1607.	5.0	5
53	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , 2018, 53, 787-790.	2.4	5
54	Are pathogenic intestinal bacteria present in stool specimens from patients with chronic heart failure?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 141-143.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 22-27.	1.8	5
56	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. <i>Transplant Infectious Disease</i> , 2021, 23, e13627.	1.7	5
57	Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. <i>Transplant International</i> , 2016, 29, 1196-1204.	1.6	4
58	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020, 22, e13440.	1.7	4
59	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	1.0	4
60	Cytomegalovirus-specific T cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. <i>British Journal of Haematology</i> , 2021, 195, 637-641.	2.5	4
61	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2018, 90, 1375-1382.	5.0	3
62	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 405-414.	4.8	3
63	Spontaneously resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , 2019, 91, 1128-1135.	5.0	3
64	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. <i>Bone Marrow Transplantation</i> , 2021, 56, 1281-1290.	2.4	3
65	Human pegivirus type 1 infection in kidney transplant recipients: Replication kinetics and clinical correlates. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	3
66	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1510-1512.	4.0	2
67	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	3.3	2
68	A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score. <i>Journal of Infectious Diseases</i> , 2020, 222, 479-487.	4.0	2
69	Assessing the risk of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma. <i>Journal of General Virology</i> , 2017, 98, 1855-1863.	2.9	2
70	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018, 67, 814-819.	1.8	2
71	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	2.4	2
72	Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting. <i>Clinical Transplantation</i> , 2014, 28, 508-511.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Cytomegalovirus DNAemia in patients with <i>de novo</i> acute myeloid leukemia undergoing cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3081-3083.	1.3	0